- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04749940
PRF Based Dressing Versus AQUACEL® for Local Treatment of Skin Graft Donor Site
PRF Based Dressing Versus AQUACEL® for Local Treatment of Skin Graft Donor Site: A Non-Inferiority Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective single-blind study, where the evaluator is blinded to the treatment. Each patient will be dressed with both Aquacel® and PRF dressing. Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
3 days after surgery the patients will be asked to complete a VAS questionnaire. A week and 2 weeks after surgery, patients will have their dressing changed as in the first treatment, and will answer VAS(9) and bluebelle(10) questionnaires. The wound will be photographed again for follow-up. Three weeks, 6 weeks and 3 months after surgery the scar in the donor area will be evaluated. The photographs will be shown to the blinded evaluator, to evaluate wound healing by epithelialization estimation.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel, 3525408
- Rambam Health Care Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a small burn (2-20% TBSA), who require skin grafting.
Exclusion Criteria:
- Patients younger than 18 years
- Patients refusing hospitalization
- Patients with heavily infected wounds, which are the probable cause of bacteremia or sepsis.
- Patients with diabetes mellitus or peripheral vascular disease
- Patients under treatment of steroids or other immunosuppressing agents
- Patients with infectious diseases, i.e., HIV, HCV or HBV.
- Patients who are smokers.
- Patients with a known allergy to the dressing.
- Female patients who are pregnant or nursing, psychiatric patients and soldiers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hospitalized burn patients
Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
|
Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of percentage of wound healing after 1 week, 2 weeks and 3 weeks.
Time Frame: 3 weeks
|
Primary variables will be analyzed using ImageJ software.
|
3 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- 1. Peck MD. Epidemiology of burns throughout the world. Part I: Distribution and risk factors. Vol. 37, Burns. Burns; 2011. p. 1087-100. 2. Lee RC, Teven CM. Acute Management of Burn/Electrical Injuries. In: Song DH, editor. Neligen's Plastic Surgery. 4th ed. Elsevier Ltd; 2018. p. 391-423. 3. Ding X, Shi L, Liu C, et al. A randomized comparison study of Aquacel Ag and Alginate Silver as skin graft donor site dressings. Burns. 2013 Dec;39(8):1547-50. 4. Haith LR, Stair Buchmann ME, Ackerman BH, et al. Evaluation of Aquacel Ag for Autogenous Skin Donor Sites. J Burn Care Res. . Nov-Dec 2015;36(6):602-6. 5. Sousa F, Machado V, Botelho J, Proença L, Mendes JJ, Alves R. Effect of A-PRF Application on Palatal Wound Healing after Free Gingival Graft Harvesting: A Prospective Randomized Study. Eur J Dent [Internet]. 2020 Feb 1 [cited 2020 Sep 20];14(1):63-9. Available from: https://pubmed.ncbi.nlm.nih.gov/32168533/ 6. Chou TM, Chang HP, Wang JC. Autologous platelet concentrates in maxillofacial regenerative therapy [Internet]. Vol. 36, Kaohsiung Journal of Medical Sciences. John Wiley and Sons Inc.; 2020 [cited 2020 Sep 20]. p. 305-10. Available from: https://pubmed.ncbi.nlm.nih.gov/32052598/ 7. Somani A, Rai R. Comparison of efficacy of autologous platelet-rich fibrin versus saline dressing in chronic venous leg ulcers: A randomised controlled trial. J Cutan Aesthet Surg [Internet]. 2017 Jan 1 [cited 2020 Sep 20];10(1):8-12. Available from: https://pubmed.ncbi.nlm.nih.gov/28529414/ 8. Wang L, Liu G, Li Z, Jia BC, Wang Y. Clinical application of platelet-rich fibrin in chronic wounds combined with subcutaneous stalking sinus. Zhonghua Shao Shang Za Zhi [Internet]. 2018 Sep 20 [cited 2020 Sep 20];34(9):637-42. Available from: https://pubmed.ncbi.nlm.nih.gov/30293368/ 9. Piccin A, Di Pierro AM, Canzian L, Primerano M, Corvetta D, Negri G, et al. Platelet gel: A new therapeutic tool with great potential [Internet]. Vol. 15, Blood Transfusion. SIMTI Servizi Sri; 2017 [cited 2020 Sep 20]. p. 333-40. Available from: https://pubmed.ncbi.nlm.nih.gov/27483482/ 10. Ding Y, Cui L, Zhao Q, et al. Platelet-Rich Fibrin Accelerates Skin Wound Healing in Diabetic Mice. Ann Plast Surg. 2017 Sep;79(3):e15-e19. 11. Yüce E, Kömerik N. Potential effects of advanced platelet rich fibrin as a wound-healing accelerator in the management of alveolar osteitis: A randomized clinical trial. Niger J Clin Pract. 2019 Sep;22(9):1189-1195. 12. Alpan AL, Cin GT. PRF improves wound healing and postoperative discomfort after harvesting subepithelial connective tissue graft from palate: a randomized controlled trial. Clin Oral Investig. 2020 Jan;24(1):425-436. 13. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis [Internet]. 1978 [cited 2020 Sep 20];37(4):378-81. Available from: https://pubmed.ncbi.nlm.nih.gov/686873/ 14. Macefield R, Blazeby J, Reeves B, Brookes S, Avery K, Rogers C, et al. Validation of the Bluebelle Wound Healing Questionnaire for assessment of surgical-site infection in closed primary wounds after hospital discharge. BJS [Internet]. 2019 Feb 17 [cited 2020 Sep 20];106(3):226-35. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/bjs.11008
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0007-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment of Skin Graft Donor Site
-
Klinik BogenhausenCompletedReepithelialization of Skin Graft Donor SitesGermany
-
Aubrey Inc.UnknownTreatment of Donor Site BurnsUnited States
-
University Hospitals, LeicesterTerminatedSkin Graft | Donor Site ComplicationUnited Kingdom
-
Prof. Dr. Petra ReinkeCompletedImmunosuppressive Treatment of Living-donor Renal TransplantationGermany
-
Tang-Du HospitalCompletedDisorder of Skin Donor Site | Skin Graft Disorder | Wound Healing Disturbance of
-
NYU Langone HealthRecruiting
-
Brigham and Women's HospitalMedline IndustriesCompletedSplit-thickness Skin Graft Donor Sites
-
Molnlycke Health Care ABCompletedAcute Wound | Donor Site | Split Skin GraftSweden
-
Dow University of Health SciencesCompletedSkin Graft Scar | Donor Site ComplicationPakistan
-
Chulalongkorn UniversityNot yet recruitingWound | Skin Graft Scar | Donor Site Complication | Scar Conditions and Fibrosis of SkinThailand
Clinical Trials on Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
-
BonusBio Group LtdCompletedBone Void in the Maxillofacial AreaIsrael
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline; University of WashingtonCompletedProstate Cancer | Castration-resistant, MetastaticUnited States